uniQure Stock Soars as FDA's Vinay Prasad Exit Sparks Analyst Upgrades
uniQure stock jumps after Wells Fargo ($60 PT) and RBC ($35 PT) upgrades, driven by Vinay Prasad's FDA exit boosting AMT-130 Huntington's gene therapy outlook.
/ 9 items
#QURE↓
Vinay Prasad Leaves FDA After High-Profile Clashes Over Gene Therapies
Dr. Vinay Prasad, head of the FDA's vaccines and biologics division, is stepping down at the end of April after a controversial year overseeing approvals for vaccines, gene therapies, and biotech products.
FDA Rejects UniQure’s Huntington’s Gene Therapy Path – Shares Plunge
UniQure's stock falls sharply in premarket trading after the FDA says early data for AMT-130 isn't enough for approval. The company plans more talks for a Phase III trial on this Huntington's disease treatment.
uniQure Stock Tanks on FDA Comments – But Is It Really About AMT-130?
uniQure shares fell about 33% after FDA Commissioner Marty Makary's comments on rare disease drugs. But analysts say his remarks likely targeted another therapy, not uniQure's AMT-130 for Huntington's disease.
uniQure's Fabry Disease Gene Therapy Shows Promising Results in Early Trial
AMT-191 gene therapy demonstrates sustained enzyme activity increases in Fabry disease patients, with 6 of 11 stopping traditional infusion therapy.
uniQure Moves Forward with Huntington's Disease Treatment
uniQure secures FDA meeting to discuss accelerated approval for AMT-130, bringing hope to the Huntington's disease community with potentially life-changing gene therapy.